Etrasimod – the second generation S1P receptor modulators in ulcerative colitis therapy
Milan Lukáš1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Sandborn JW, Vermeire S, Peyrin-Biroulet L et al. Etrasimod as induction and maintenance for ulcerative colitis (ELEVATE): two randomised, double blind, placebo controlled, phase 3 study. Lancet 2023; 401(10383): 1159–1171. doi: 10.1016/S0140-6736(23)00061-2.
2. Ruguiero M, Siegmund B, Yarur AJ et al. Etrasimod for the treatment of ulcerative colitis: Analysis of infection event from the ELEVATE UC programme. J Crohns Colitis. In press 2024. doi: 10.1093/ecco-jcc/jjae060.
3. Pyerin-Biroulet L, Dubinsky M, Sands BE et al. Efficacy and safety of Etrasimod in patients with moderately to severely active isolated proctitis: Results from the phase 3 ELEVATE UC clinical programme. J Crohn’s Colitis 2024; 18(8): 1270–1282. doi: 10.1093/ecco-jcc/jjae038.